Local relapse after breast-conserving therapy for ductal carcinoma in situ: A European single-center experience and external validation of the memorial Sloan-Kettering cancer center DCIS nomogram

Cancer Journal (United States)

Volumn 20, Issue 1, 2014, Pages 1-7

  Sweldens, Caroline ^a   Peeters, Stephanie ^b   Van Limbergen, Erik ^b   Janssen, Hilde ^b   Laenen, Annouschka ^c   Patil, Sujata ^d   Van Zee, Kimberly J ^d   Weltens, Caroline ^b  

^a AZ Delta   (Belgium)

^b UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^c Leuven Biostatistics and Statistical Bioinformatics Centre   (Belgium)

^d MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Breast cancer; breast conserving surgery; ductal carcinoma in situ; ipsilateral relapse; nomogram; radiotherapy

Indexed keywords

ADULT; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER HORMONE THERAPY; CANCER PROGNOSIS; CANCER SURGERY; DISEASE ASSOCIATION; FEMALE; FOLLOW UP; HUMAN; INTRADUCTAL CARCINOMA; IPSILATERAL BREAST TUMOR RELAPSE; MAJOR CLINICAL STUDY; MIDDLE AGED; NOMOGRAM; PARTIAL MASTECTOMY; PREDICTOR VARIABLE; PRIORITY JOURNAL; RECURRENCE RISK; RETROSPECTIVE STUDY; TUMOR RECURRENCE; VALIDATION STUDY; VERY ELDERLY; CARCINOMA, DUCTAL, BREAST; CARCINOMA, INTRADUCTAL, NONINFILTRATING; EUROPE; PATHOLOGY; PREDICTIVE VALUE; PROGNOSIS; UNITED STATES;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, DUCTAL, BREAST; CARCINOMA, INTRADUCTAL, NONINFILTRATING; EUROPE; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NOMOGRAMS; PREDICTIVE VALUE OF TESTS; PROGNOSIS; UNITED STATES;

EID: 84893555175     PISSN: 15289117     EISSN: 1540336X     Source Type: Journal    
DOI: 10.1097/PPO.0000000000000025     Document Type: Article

References (31)

1. Kerlikowske K. Epidemiology of ductal carcinoma in situ. J Natl Cancer Inst Monogr. 2010;41:139-141.
2. Ernster VL, Ballard-Barbash R, Barlow WE, et al. Detection of ductal carcinoma in situ in women undergoing screening mammography. J Natl Cancer Inst. 2002;94:1546-1554.
3. Bijker N, Meijnen P, Peterse JL, et al. Breast-conserving treatment with or without radiotherapy in ductal carcinoma-in-situ: ten-year results of European Organisation for Research and Treatment of Cancer randomized phase III trial 10853-a study by the EORTC Breast Cancer Cooperative Group and EORTC Radiotherapy Group. J Clin Oncol. 2006;24:3381-3387.
4. Correa C, McGale P, Taylor C, et al. Overview of the randomized trials of radiotherapy in ductal carcinoma in situ of the breast. Early Breast Cancer Trialists Collaborative Group (EBCTCG). J Natl Cancer Inst. 2010;41:162-177.
5. Wapnir IL, Dignam JJ, Fischer B, et al. Long-term outcomes of invasive ipsilateral breast tumor recurrences after lumpectomy in NSABP B-17 and B-24 randomized clinical trials for DCIS. J Natl Cancer Inst. 2011; 103:478-488.
6. Fisher ER, Dignam J, Tan-Chiu E, et al. Pathologic findings from the National Surgical Adjuvant Breast Project (NSABP) eight-year update of protocol B-17: intraductal carcinoma. Cancer. 1999;86:429-438.
7. Holmberg L, Garmo H, Granstrand B, et al. Absolute risk reductions for local recurrence after postoperative radiotherapy after sector resection for ductal carcinoma in situ of the breast. J Clin Oncol. 2008;26: 1247-1252.
8. Clarke M, Collins R, Darby S, et al. Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005;366:2087-2106.
9. Cuzick J, Sestak I, Pinder SE, et al. Effect of tamoxifen and radiotherapy in women with locally excised ductal carcinoma in situ: long-term results from the UK/ANZ DCIS trial. Lancet Oncol. 2011;12:21-29.
10. Ceilley E, Jagsi R, Goldberg S, et al. The management of ductal carcinoma in situ in North America and Europe. Results of a survey. Cancer. 2004;101:1958-1967.
11. Rudloff U, Jacks LM, Goldberg JI, et al. Nomogram for predicting the risk of local recurrence after breast-conserving surgery for ductal carcinoma in situ. J Clin Oncol. 2010;28:3762-3769.
12. Heagerty PJ, Zheng Y. Surival model predictive accuracy and ROC curves. Biometrics. 2005;61:92-105.
13. Gonen M, Heller G. Concordance probability and discriminatory power in proportional hazards regression. Biometrika. 2005;92:65-970.
14. Harrel FE, Lee KL, Mark DB. Multivariable prognostic models: issues developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Statistics in medicine. 1996;15:361-387.
15. Rubin D. Inference and missing data. Biometrika. 1976;63:581-592.
16. Rubin D. Multiple Imputation for Non-response in Surveys. New York: Wiley; 1987.
17. EBCTC Group. Favorable and unfavorable effects on long-term survival of radiotherapy for early breast cancer: an overview of the randomized trials. Lancet. 2000;20:1757-1770.
18. Giordano S, Kuo Y, Freeman J, et al. Risk of cardiac death after adjuvant radiotherapy for breast cancer. J Natl Cancer Inst. 2005;97: 419-424.
19. Darby S, McGale P, Taylor C, et al. Long-term mortality from heart disease and lung cancer after radiotherapy for early breast cancer: prospective cohort study of about 300,000 women un US SEER cancer registries. Lancet Oncol. 2005;6:557-565.
20. Kattan MW, Wheeler TM, Scardino PT. Postoperative nomogram for disease recurrence after radical prostatectomy for prostate cancer. J Clin Oncol. 1999;17:1499-1507.
21. Stephenson AJ, Scardino PT, Eastham JA, et al. Postoperative nomogram predicting the 10-year probability of prostate cancer recurrence after radical prostatectomy. J Clin Oncol. 2005;23:7005-7012.
22. Kattan MW, Karpeh MS, Mazumdar M, et al. Postoperative nomogram for diseaseYspecific survival after an R0 resection for gastric carcinoma. J Clin Oncol. 2003;21:3647-3650.
23. Brennan MF, Kattan MW, Klimstra D, et al. Prognostic nomogram for patients undergoing resection for adenocarcinoma of the pancreas. Ann Surg. 2004;240:293-298.
24. Weiser MR, Landmann RG, Kattan MW, et al. Individualized prediction of colon cancer recurrence using a nomogram. J Clin Oncol. 2008; 26,380-385.
25. Goldstein LJ, Gray R, Badve S, et al. Prognostic utility of the 21- gene assay in hormone receptorYpositive operable breast cancer compared with classical clinicopathologic features. J Clin Oncol. 2008;26: 4063-4071.
26. van la Parra RFD, Ernst MF, Bevilacqua JLB, et al. Validation of a nomogram to predict the risk of nonsentinel lymph node metastases in breast cancer patients with a positive sentinel node biopsy: validation of the MSKCC breast nomogram. Ann Surg Oncol. 2009;16:1128-1135.
27. Ballehaninna UK, Chamberlain RS. Inclusion of tumor biology molecular markers to improve the ductal carcinoma in situ ipsilateral breast tumor recurrence nomogram predictability. J Clin Oncol. 2011;29:e97-e98; author reply e99. 2010.
28. Ringberg A, Nordgren H, Thorstensson S, et al. Histopathological risk factors for ipsilateral breast events after breast conserving treatment for ductal carcinoma in situ of the breast: results from the Swedish randomized trial. Eur J Cancer. 2007;43:291-298.
29. Dunne C, Burke JP, Morrow M, et al. Effect of margin status on local recurrence after breast conserving and radiation therapy for ductal carcinoma in situ. J Clin Oncol. 2009;27:1615-1620.
30. Silverstein MJ, Lagios MD, Groshen S, et al. The influence of margin width on local control of ductal carcinoma in situ of the breast. N Engl J Med. 1999;340:1455-1461.
31. Yi M, Meric-Bernstam F, Kuerer HM, et al. Evaluation of a breast cancer nomogram for predicting risk of ipsilateral breast tumor recurrences in patients with ductal carcinoma in situ after local excision. J Clin Oncol. 2012;30:600-607.